Eric Cui, Jackson W Durbin, Amy Zhao, Andrew Fealy, Philip M Parel, Rachel Ranson, Theodore Quan, Sabrina Gill, Amil Agarwal, Bella Gomez, Sandesh Rao, Savyasachi C Thakkar
{"title":"Risk Factors for Periprosthetic Fractures Following Total Hip Arthroplasty in Patients Younger Than 50 Years.","authors":"Eric Cui, Jackson W Durbin, Amy Zhao, Andrew Fealy, Philip M Parel, Rachel Ranson, Theodore Quan, Sabrina Gill, Amil Agarwal, Bella Gomez, Sandesh Rao, Savyasachi C Thakkar","doi":"10.1016/j.arth.2025.08.069","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>With the expansion of total hip arthroplasty (THA) into younger populations, the number of periprosthetic fractures (PPF) seen amongst young patients is expected to increase. Therefore, the aim of this study was to identify risk factors for PPF following THA in patients under 50 years.</p><p><strong>Methods: </strong>In total, 270,986 patients were included in this study. Patients who underwent primary THA with subsequent PPF within two years of surgery were stratified into five age cohorts: under 20, 21 to 30, 31 to 40, 41 to 50, and 51 to 60 years of age. Risk factors were identified using multivariate regression with the age 51-60 years cohort as reference. After applying the Bonferroni correction, a P-value of less than 0.03 was used as the cutoff for significance. All statistical analysis was conducted using R software (Vienna, Austria).</p><p><strong>Results: </strong>In patients under the age of 50 years, risk factors for PPF included undergoing THA for osteonecrosis (OR (odds ratio): 1.5; P < 0.001). Other risk factors included a history of arrhythmia (OR: 1.4; P < 0.001), peripheral vascular disease (OR: 1.2; P = 0.002), paralysis (OR: 1.3; P = 0.03), neurologic disease (OR: 1.8; P < 0.001), pulmonary disease (OR: 1.3; P < 0.001), chronic kidney disease (OR: 1.3; P < 0.001), anemia with blood loss (OR: 1.6; P = 0.01), and alcohol abuse (OR: 1.9; P = 0.001). Protective factors included hip osteoarthritis (OR: 0.8; P < 0.001), men (OR: 0.7; P < 0.001), and age of 40 to 50 years (OR: 0.8; P < 0.001).</p><p><strong>Conclusion: </strong>Several risk factors for PPFs following THA in patients under age 50 years were identified. Of note, hip osteoarthritis, men, and age 41 to 50 years were protective factors against PPFs. As the proportion of younger patients undergoing THA continues to increase, our results can be used to guide surgeons in identifying patients at increased risk for PPF and improve patient outcomes.</p>","PeriodicalId":51077,"journal":{"name":"Journal of Arthroplasty","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Arthroplasty","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.arth.2025.08.069","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: With the expansion of total hip arthroplasty (THA) into younger populations, the number of periprosthetic fractures (PPF) seen amongst young patients is expected to increase. Therefore, the aim of this study was to identify risk factors for PPF following THA in patients under 50 years.
Methods: In total, 270,986 patients were included in this study. Patients who underwent primary THA with subsequent PPF within two years of surgery were stratified into five age cohorts: under 20, 21 to 30, 31 to 40, 41 to 50, and 51 to 60 years of age. Risk factors were identified using multivariate regression with the age 51-60 years cohort as reference. After applying the Bonferroni correction, a P-value of less than 0.03 was used as the cutoff for significance. All statistical analysis was conducted using R software (Vienna, Austria).
Results: In patients under the age of 50 years, risk factors for PPF included undergoing THA for osteonecrosis (OR (odds ratio): 1.5; P < 0.001). Other risk factors included a history of arrhythmia (OR: 1.4; P < 0.001), peripheral vascular disease (OR: 1.2; P = 0.002), paralysis (OR: 1.3; P = 0.03), neurologic disease (OR: 1.8; P < 0.001), pulmonary disease (OR: 1.3; P < 0.001), chronic kidney disease (OR: 1.3; P < 0.001), anemia with blood loss (OR: 1.6; P = 0.01), and alcohol abuse (OR: 1.9; P = 0.001). Protective factors included hip osteoarthritis (OR: 0.8; P < 0.001), men (OR: 0.7; P < 0.001), and age of 40 to 50 years (OR: 0.8; P < 0.001).
Conclusion: Several risk factors for PPFs following THA in patients under age 50 years were identified. Of note, hip osteoarthritis, men, and age 41 to 50 years were protective factors against PPFs. As the proportion of younger patients undergoing THA continues to increase, our results can be used to guide surgeons in identifying patients at increased risk for PPF and improve patient outcomes.
导言:随着全髋关节置换术(THA)在年轻人群中的应用,年轻患者中假体周围骨折(PPF)的数量预计会增加。因此,本研究的目的是确定50岁以下患者THA后PPF的危险因素。方法:共纳入270,986例患者。在手术两年内接受原发性THA并随后PPF的患者被分为5个年龄组:20岁以下、21至30岁、31至40岁、41至50岁和51至60岁。以51-60岁队列为参考,采用多因素回归方法确定危险因素。应用Bonferroni校正后,p值小于0.03作为显著性的截止值。所有统计分析使用R软件(维也纳,奥地利)进行。结果:在50岁以下的患者中,PPF的危险因素包括因骨坏死而接受THA (OR(优势比):1.5;P < 0.001)。其他危险因素包括心律失常(OR: 1.4; P < 0.001)、周围血管疾病(OR: 1.2; P = 0.002)、瘫痪(OR: 1.3; P = 0.03)、神经系统疾病(OR: 1.8; P < 0.001)、肺部疾病(OR: 1.3; P < 0.001)、慢性肾脏疾病(OR: 1.3; P < 0.001)、贫血伴失血(OR: 1.6; P = 0.01)和酗酒(OR: 1.9; P = 0.001)。保护因素包括髋关节骨关节炎(OR: 0.8; P < 0.001)、男性(OR: 0.7; P < 0.001)和40 - 50岁(OR: 0.8; P < 0.001)。结论:确定了50岁以下患者THA后发生PPFs的几个危险因素。值得注意的是,髋关节骨关节炎、男性和年龄在41 - 50岁的人是预防PPFs的保护因素。随着接受全髋关节置换术的年轻患者比例持续增加,我们的研究结果可用于指导外科医生识别PPF风险增加的患者并改善患者预后。
期刊介绍:
The Journal of Arthroplasty brings together the clinical and scientific foundations for joint replacement. This peer-reviewed journal publishes original research and manuscripts of the highest quality from all areas relating to joint replacement or the treatment of its complications, including those dealing with clinical series and experience, prosthetic design, biomechanics, biomaterials, metallurgy, biologic response to arthroplasty materials in vivo and in vitro.